Addeira Pharmaceuticals
Addeira Pharmaceuticals, a prominent player in the pharmaceutical industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2010, the company has rapidly established itself as a leader in innovative drug development, focusing on therapeutic areas such as oncology and neurology. Addeira's core offerings include advanced biologics and targeted therapies, distinguished by their commitment to enhancing patient outcomes through cutting-edge research and development. The company has achieved significant milestones, including several successful product launches that have garnered recognition within the healthcare community. With a strong market position, Addeira Pharmaceuticals continues to push the boundaries of medical science, striving to deliver unique solutions that address unmet medical needs and improve the quality of life for patients worldwide.
DitchCarbon Score
How does Addeira Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Addeira Pharmaceuticals's score of 9 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Addeira Pharmaceuticals's reported carbon emissions
Addeira Pharmaceuticals, headquartered in Sweden, has set ambitious climate commitments despite not having specific carbon emissions data available. The company has committed to reducing its Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 42% by the year 2030, using 2022 as the baseline year. This target has been validated through the Science Based Targets initiative (SBTi) and aligns with the necessary reductions to limit global warming to 1.5°C. In addition to its direct emissions reduction goals, Addeira Pharmaceuticals is also focused on measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. These commitments reflect the company's proactive approach to addressing climate change and its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Addeira Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
